Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Ever since Ariad Pharmaceuticals’ Ponatinib treatment for leukemia was given the green light by American regulator, the FDA, industry majors have been sniffing around. As its shares changed hands at $6.50, valuing the Massachusetts-based company at around £800m, dealers heard whispers from across the Pond that at least three international pharma groups including US giant Eli Lilly have made ‘friendly approaches’ to the Ariad board and are prepared to pay up to $20 a share in cash to gain control. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock opened at $7.28 in last session, and closed at $7.52, while the day range of ARIA stock is $7.05 – $7.56. The stock showed a positive weekly performance of 13.60 %.
CEL-SCI Corporation (NYSEMKT:CVM) To say that 2014 has been a good year so far for CEL-SCI Corporation (NYSEMKT:CVM) would be an understatement. It’s been a great year for the company, and more specifically, its shareholders. CVM is up 96% year-to-date, cutting into a big chunk of the loss that was suffered in 2013. And, though a near-doubling in less than a month would normally be an invitation to a painful wave of profit-taking, in the case of CEL-SCI, the situation says this is one of those rallies that could get hotter the hotter it gets. CEL-SCI Corporation (NYSEMKT:CVM) stock opened at $1.09, in last session and closed at $1.16, by gaining 12.62%. The 52 week range of $0.53 – $3.09. Company’s market capitalization is $64.70 million.
Nektar Therapeutics (NASDAQ:NKTR) announced that it has priced underwritten public offering of 8.5 million shares of common stock at $12.75 per share. Nektar Therapeutics (NASDAQ:NKTR) stock advanced 6.79% and finished the last session at $13.99. The EPS of the stock remained -1.45. Company’s market capitalization is $1.62 billion.
One under-$10 biotechnology player that’s starting to trend within range of triggering a major breakout trade is Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY), which is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) stock opened the session at $1.78, and closed the session at $1.86. The 52 week range of the ONCY stock remained $1.45 – $4.93 and the day range was $1.72 – $1.90.
Leave a Reply